prednisolone has been researched along with Ache in 160 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
Excerpt | Relevance | Reference |
---|---|---|
"Biomarkers reflecting tissue turnover and inflammation [aggrecanase-derived neoepitope of arggecan (ARGS), MMP-derived neoepitope of type I collagen (C1M), MMP-derived neoepitope of type III collagen (C3M), marker of true type V collagen formation (PROC5), MMP-derived neoepitope of CRP (CRPM), citrullinated vimentin fragment (VICM), high-sensitivity (hsCRP)] were measured in sera from 78 patients with painful inflammatory hand OA, who were randomized between prednisolone or placebo treatment." | 9.69 | Serum biomarkers in prednisolone-treated hand osteoarthritis patients. ( Bay-Jensen, AC; Kloppenburg, M; Kroon, FPB; Thudium, CF; van de Stadt, LA, 2023) |
"This pragmatic, prospective, double-blind, double-dummy, parallel-group, randomized, non-inferiority trial investigates whether prednisolone (intervention) is non-inferior to treatment with colchicine (active control) in patients with acute gout." | 9.69 | Prednisolone Versus Colchicine for Acute Gout in Primary Care (COPAGO): protocol for a two-arm multicentre, pragmatic, prospective, randomized, double-blind, controlled clinical trial of prednisolone and colchicine for non-inferiority with a parallel grou ( Böhm, S; Bülow, R; Chenot, JF; Dörr, M; Engeli, S; Freyer Martins Pereira, J; Gágyor, I; Greser, A; Hummers, E; Kamin, P; Richter, A; Schuster, F; Stracke, S; Truthmann, J; Witte, A, 2023) |
"Data were analysed from a 6-week, randomized, double-blind, placebo-controlled trial investigating prednisolone treatment in 92 patients with painful inflammatory hand OA." | 9.51 | Neuropathic-like pain symptoms in inflammatory hand osteoarthritis lower quality of life and may not decrease under prednisolone treatment. ( Allaart, CF; Böhringer, S; Boonen, AERCH; Kloppenburg, M; Kortekaas, MC; Kroon, FPB; Niesters, M; Reijnierse, M; Riyazi, N; Rosendaal, FR; Starmans-Kool, M; Turkstra, F; van de Stadt, LA; van der Meulen, C; van Zeben, J, 2022) |
"To compare the effectiveness and safety of oral prednisolone versus oral indomethacin in patients presenting to emergency departments (EDs) with acute gout." | 9.22 | Oral Prednisolone in the Treatment of Acute Gout: A Pragmatic, Multicenter, Double-Blind, Randomized Trial. ( Cheng, CH; Choi, YF; Graham, CA; Janssens, HJ; Lee, KH; Man, CY; Rainer, TH; Tam, LS; Yau, WH, 2016) |
"Prednisolone and/or valacyclovir did not affect the incidence or intensity of ipsilateral pain in Bell's palsy." | 9.14 | The course of pain in Bell's palsy: treatment with prednisolone and valacyclovir. ( Axelsson, S; Berg, T; Engström, M; Jonsson, L; Kanerva, M; Pitkäranta, A; Stjernquist-Desatnik, A, 2009) |
"Bucillamine (Buc), developed in Japan, is a disease-modifying antirheumatic drug (DMARD) which has been used to treat numerous patients with rheumatoid arthritis (RA) in Japan and Korea with favorable results." | 9.14 | A comparative study of the effects of bucillamine and salazosulfapyridine in the treatment of rheumatoid arthritis. ( Abe, M; Kinoshita, M; Nakajima, M; Ohara, H; Ueda, N, 2009) |
"The results of this study suggest that SKI306X was generally well tolerated and not inferior to celecoxib in regard to pain relief in these Korean patients with RA." | 9.12 | Assessment of comparative pain relief and tolerability of SKI306X compared with celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, double-dummy, phase III, noninferiority clinical trial. ( Baek, HJ; Cha, HS; Jung, HG; Kang, SW; Kim, HA; Koh, EM; Lee, CK; Lee, EY; Lee, YJ; Song, YW; Suh, Y; Yoo, B, 2007) |
"Bucillamine (Buc) is a disease-modifying antirheumatic drug (DMARD) developed in Japan, which has been used as one of the first-line DMARDs for the treatment of rheumatoid arthritis (RA) in Japan." | 9.12 | Efficacy profile of bucillamine in rheumatoid arthritis patients in a large observational cohort study, IORRA. ( Hara, M; Inoue, E; Iwatani, M; Kamatani, N; Nakajima, A; Nakamura, T; Tomatsu, T; Yamanaka, H, 2006) |
"Indomethacin, 100 mg orally, was compared with prednisolone, 5 mg, as addititional therapy at night, in a two-week, double-blind, between-patient study in twenty-four in-patients with rheumatoid arthritis." | 9.04 | Indomethacin or prednisolone at night in rheumatoid arthritis? ( Murthy, MH; Rhymer, AR; Wright, V, 1978) |
"Prednisolone in low doses (< or = 15 mg daily) may be used intermittently in patients with rheumatoid arthritis, particularly if the disease cannot be controlled by other means." | 8.80 | Meta-analysis of short-term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. ( Gøtzsche, PC; Johansen, HK, 1998) |
"Severe hyponatremia is rare when carbamazepine is used as monotherapy." | 7.88 | Walking hyponatremia syndrome of inappropriate antidiuretic hormone secretion secondary to carbamazepine use: a case report. ( Palacios Argueta, PJ; Pineda, A; Sánchez Rosenberg, GF, 2018) |
"Adhesive capsulitis or frozen shoulder is a common condition characterized by shoulder pain and stiffness in which conservative methods of treatment such as glucocorticosteroids, anti-inflammatory drugs, and physiotherapy play a significant part." | 6.73 | Pain relieving effect of short-course, pulse prednisolone in managing frozen shoulder. ( Haghighi, MH; Hemmati, AA; Saeidian, SR, 2007) |
"Pamidronate treatment also did not have any influence on patient survival or on the frequency of hypercalcaemia." | 6.69 | Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group. ( Abildgaard, N; Brincker, H; Ford, J; Gimsing, P; Hedenus, M; Kandra, A; Turesson, I; Westin, J, 1998) |
"This pragmatic, prospective, double-blind, double-dummy, parallel-group, randomized, non-inferiority trial investigates whether prednisolone (intervention) is non-inferior to treatment with colchicine (active control) in patients with acute gout." | 5.69 | Prednisolone Versus Colchicine for Acute Gout in Primary Care (COPAGO): protocol for a two-arm multicentre, pragmatic, prospective, randomized, double-blind, controlled clinical trial of prednisolone and colchicine for non-inferiority with a parallel grou ( Böhm, S; Bülow, R; Chenot, JF; Dörr, M; Engeli, S; Freyer Martins Pereira, J; Gágyor, I; Greser, A; Hummers, E; Kamin, P; Richter, A; Schuster, F; Stracke, S; Truthmann, J; Witte, A, 2023) |
"Biomarkers reflecting tissue turnover and inflammation [aggrecanase-derived neoepitope of arggecan (ARGS), MMP-derived neoepitope of type I collagen (C1M), MMP-derived neoepitope of type III collagen (C3M), marker of true type V collagen formation (PROC5), MMP-derived neoepitope of CRP (CRPM), citrullinated vimentin fragment (VICM), high-sensitivity (hsCRP)] were measured in sera from 78 patients with painful inflammatory hand OA, who were randomized between prednisolone or placebo treatment." | 5.69 | Serum biomarkers in prednisolone-treated hand osteoarthritis patients. ( Bay-Jensen, AC; Kloppenburg, M; Kroon, FPB; Thudium, CF; van de Stadt, LA, 2023) |
"This randomized double-blinded trial aimed to compare the anesthetic success of inferior alveolar nerve blocks (IANBs) with 2% lidocaine in mandibular molars with symptomatic irreversible pulpitis (SIP) after oral premedication of prednisolone, dexamethasone, and ketorolac with placebo." | 5.69 | Effect of Preoperative Oral Steroids in Comparison to Anti-inflammatory on Anesthetic Success of Inferior Alveolar Nerve Block in Mandibular Molars with Symptomatic Irreversible Pulpitis-A Double-blinded Randomized Clinical Trial. ( Hegde, V; Kulkarni, V; Nagendrababu, V; Setzer, FC; Shaikh, S; Shanmugasundaram, S; Suresh, N, 2023) |
"KEY MESSAGESLow initial dose (15 mg/d) of prednisolone was non-inferior to the standard initial dose of prednisolone (30 mg/d) in treatment duration, time to pain relief, or the prevalence of hypothyroidism, recurrence, and adverse reactions in the treatment of subacute thyroiditis." | 5.69 | Comparison of the therapeutic effects of 15 mg and 30 mg initial daily prednisolone doses in patients with subacute thyroiditis: a multicenter, randomized, open-label, parallel-controlled trial. ( Gao, B; Gao, L; Jia, A; Jiao, Y; Jing, X; Shang, L; Wang, J; Xing, Y; Xu, J; Xu, S; Xu, W; Zeng, J; Zhang, J, 2023) |
"Data were analysed from a 6-week, randomized, double-blind, placebo-controlled trial investigating prednisolone treatment in 92 patients with painful inflammatory hand OA." | 5.51 | Neuropathic-like pain symptoms in inflammatory hand osteoarthritis lower quality of life and may not decrease under prednisolone treatment. ( Allaart, CF; Böhringer, S; Boonen, AERCH; Kloppenburg, M; Kortekaas, MC; Kroon, FPB; Niesters, M; Reijnierse, M; Riyazi, N; Rosendaal, FR; Starmans-Kool, M; Turkstra, F; van de Stadt, LA; van der Meulen, C; van Zeben, J, 2022) |
"In these prespecified exploratory analyses, there was no significant difference in pain or HRQOL when olaparib was added to abiraterone." | 5.51 | Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial. ( Alekseev, B; Burgents, J; Chiuri, VE; Clarke, NW; Degboe, A; Fléchon, A; Gresty, C; Jassem, J; Jones, R; Kang, J; Kocak, I; Redfern, C; Saad, F; Sala, N; Thiery-Vuillemin, A; Wiechno, P, 2022) |
"In type I Gaucher's disease, episodes of severe disabling bone pain, the so called bone crises, may be resistant to all analgesics, including narcotics." | 5.29 | Effective treatment of painful bone crises in type I gaucher's disease with high dose prednisolone. ( Cohen, IJ; Katz, K; Kornreich, L; Mekhmandarov, S; Zaizov, R, 1996) |
"To compare the effectiveness and safety of oral prednisolone versus oral indomethacin in patients presenting to emergency departments (EDs) with acute gout." | 5.22 | Oral Prednisolone in the Treatment of Acute Gout: A Pragmatic, Multicenter, Double-Blind, Randomized Trial. ( Cheng, CH; Choi, YF; Graham, CA; Janssens, HJ; Lee, KH; Man, CY; Rainer, TH; Tam, LS; Yau, WH, 2016) |
"Prednisolone and/or valacyclovir did not affect the incidence or intensity of ipsilateral pain in Bell's palsy." | 5.14 | The course of pain in Bell's palsy: treatment with prednisolone and valacyclovir. ( Axelsson, S; Berg, T; Engström, M; Jonsson, L; Kanerva, M; Pitkäranta, A; Stjernquist-Desatnik, A, 2009) |
"Bucillamine (Buc), developed in Japan, is a disease-modifying antirheumatic drug (DMARD) which has been used to treat numerous patients with rheumatoid arthritis (RA) in Japan and Korea with favorable results." | 5.14 | A comparative study of the effects of bucillamine and salazosulfapyridine in the treatment of rheumatoid arthritis. ( Abe, M; Kinoshita, M; Nakajima, M; Ohara, H; Ueda, N, 2009) |
"To test a new drug for patients with recurrent oral aphthae nonresponsive to local corticosteroid therapy, we compared the therapeutic effectiveness and adverse effects of systemic prednisone and systemic montelukast in a placebo-controlled trial." | 5.14 | Pilot study on recurrent aphthous stomatitis (RAS): a randomized placebo-controlled trial for the comparative therapeutic effects of systemic prednisone and systemic montelukast in subjects unresponsive to topical therapy. ( Buonaiuto, C; Cirillo, N; Femiano, F; Gombos, F; Lanza, A, 2010) |
"Bucillamine (Buc) is a disease-modifying antirheumatic drug (DMARD) developed in Japan, which has been used as one of the first-line DMARDs for the treatment of rheumatoid arthritis (RA) in Japan." | 5.12 | Efficacy profile of bucillamine in rheumatoid arthritis patients in a large observational cohort study, IORRA. ( Hara, M; Inoue, E; Iwatani, M; Kamatani, N; Nakajima, A; Nakamura, T; Tomatsu, T; Yamanaka, H, 2006) |
"The results of this study suggest that SKI306X was generally well tolerated and not inferior to celecoxib in regard to pain relief in these Korean patients with RA." | 5.12 | Assessment of comparative pain relief and tolerability of SKI306X compared with celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, double-dummy, phase III, noninferiority clinical trial. ( Baek, HJ; Cha, HS; Jung, HG; Kang, SW; Kim, HA; Koh, EM; Lee, CK; Lee, EY; Lee, YJ; Song, YW; Suh, Y; Yoo, B, 2007) |
"To compare the effectiveness of a steroid injection (25 mg/ml prednisolone acetate) with a local anaesthetic control in the treatment of heel pain and to determine any advantage for patients' comfort of using a posterior tibial nerve block to anesthetize the heel prior to infiltration." | 5.09 | Steroid injection for heel pain: evidence of short-term effectiveness. A randomized controlled trial. ( Atkins, D; Crawford, F; Edwards, J; Young, P, 1999) |
"Prednisolone reduced the progression of joint destruction over 2 yr in early, active rheumatoid arthritis." | 5.08 | Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. ( Hickling, P; Jacoby, RK; Kirwan, JR, 1998) |
"Both prednisolone and papase are effective in reducing the oral surgical sequelae of trismus and pain, although prednisolone apparently is the more potent drug." | 5.04 | Double-blind study of prednisolone and papase as inhibitors of complications after oral surgery. ( Caci, F; Gluck, GM, 1976) |
"Indomethacin, 100 mg orally, was compared with prednisolone, 5 mg, as addititional therapy at night, in a two-week, double-blind, between-patient study in twenty-four in-patients with rheumatoid arthritis." | 5.04 | Indomethacin or prednisolone at night in rheumatoid arthritis? ( Murthy, MH; Rhymer, AR; Wright, V, 1978) |
"Prednisolone in low doses (< or = 15 mg daily) may be used intermittently in patients with rheumatoid arthritis, particularly if the disease cannot be controlled by other means." | 4.80 | Meta-analysis of short-term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. ( Gøtzsche, PC; Johansen, HK, 1998) |
"Severe hyponatremia is rare when carbamazepine is used as monotherapy." | 3.88 | Walking hyponatremia syndrome of inappropriate antidiuretic hormone secretion secondary to carbamazepine use: a case report. ( Palacios Argueta, PJ; Pineda, A; Sánchez Rosenberg, GF, 2018) |
" Intravenous administration of prednisolone was initiated on suspicion of lacrimal gland inflammation (pseudotumor)." | 3.76 | Case of lacrimal gland inflammation associated with ulcerative colitis. ( Katsumura, N; Mochizuki, K; Sawada, A, 2010) |
" Given the circumstantial evidence of a beneficial effect of prednisolone on pain and paresis, this report evaluates the effects of prednisolone treatment administered in the acute phase in a retrospective case series of 50 NA patients." | 3.75 | Evaluation of prednisolone treatment in the acute phase of neuralgic amyotrophy: an observational study. ( Berrevoets, M; Pillen, S; van Alfen, N; van der Wilt, GJ; van Eijk, JJ; van Engelen, BG, 2009) |
" The presenting symptoms were reduced vision and pain around the left eye." | 3.67 | Juxtapapillary chorioretinitis in neurosyphilis. A case report. ( Eide, N; Skjeldal, O, 1984) |
"50 consecutive patients of untreated lateral epicondylitis were enrolled." | 2.78 | Comparison of short term results of single injection of autologous blood and steroid injection in tennis elbow: a prospective study. ( Bachhal, V; Banshiwal, RC; Gaury, Y; Jindal, N; Lamoria, R, 2013) |
"We conclude that transplantation of autologous BMC via LP is a feasible and safe technique, but at the moment, no clear answer can be given regarding the clinical potential, despite a potential tendency to treat SCI patients, observed through statistics." | 2.77 | Clinical safety and primary efficacy of bone marrow mesenchymal cell transplantation in subacute spinal cord injured patients. ( Eskandary, H; Karamouzian, S; Nakhaee, N; Nematollahi-Mahani, SN, 2012) |
"Adhesive capsulitis or frozen shoulder is a common condition characterized by shoulder pain and stiffness in which conservative methods of treatment such as glucocorticosteroids, anti-inflammatory drugs, and physiotherapy play a significant part." | 2.73 | Pain relieving effect of short-course, pulse prednisolone in managing frozen shoulder. ( Haghighi, MH; Hemmati, AA; Saeidian, SR, 2007) |
"Pamidronate treatment also did not have any influence on patient survival or on the frequency of hypercalcaemia." | 2.69 | Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group. ( Abildgaard, N; Brincker, H; Ford, J; Gimsing, P; Hedenus, M; Kandra, A; Turesson, I; Westin, J, 1998) |
"Orthoptic examination revealed 6th nerve palsy." | 2.44 | Idiopathic orbital inflammation with extensive intra- and extracranial extension presenting as 6th nerve palsy--a case report and literature review. ( Chaudhary, N; Gibson, A; Olver, J; Tay, E, 2008) |
"We assessed Demographic data, the Systemic Lupus Erythematosus Activity Index, the Systemic Lupus International Collaborating Clinics Damage Index, Numeric Rating Scale, Fatigue Severity Scale, Body Image Scale, and the ENRICHD Social Support Instrument." | 1.72 | Prevalence and biopsychosocial factors associated with depressive symptoms among patients living with systemic lupus erythematosus in clinical settings in urban Thailand. ( Narupan, N; Pumpuang, W; Seeherunwong, A, 2022) |
"Prednisolone was administered postoperatively." | 1.43 | IgG4-related disease presenting with destructive sinonasal lesion mimicking malignancy. ( Chen, BN, 2016) |
"SD tooth pain was triggered in many vital teeth by cold and/or hot water (84." | 1.43 | Dentin hypersensitivity-like tooth pain seen in patients receiving steroid therapy: An exploratory study. ( Aida, J; Endo, Y; Harigae, H; Iikubo, M; Ishii, T; Sakamoto, M; Sasano, T; Shoji, N, 2016) |
"She had a history of pemphigus vulgaris maintained in remission with azathioprine, with no evidence of active oral or cutaneous disease at the time of presentation." | 1.42 | A patient with odynophagia and unusual endoscopic findings. ( Chatu, S; Chung-Faye, G; Griffin, J; Potts, J, 2015) |
"pain was -19." | 1.42 | Interplay between patient global assessment, pain, and fatigue and influence of other clinical disease activity measures in patients with active rheumatoid arthritis. ( Egsmose, EL; Madsen, OR, 2015) |
"The association of focal myositis with haemodialysis has been reported once previously, but we report the third case in our experience and argue that it is probably more common than previously appreciated." | 1.40 | Acute exacerbation of previously undiagnosed chronic focal myositis in an Aboriginal patient on maintenance haemodialysis. ( Majoni, SW; Stewart, BJ, 2014) |
"Propranolol is a non-selective β adrenergic receptor blocker which antagonises the anti-inflammatory effect of non-steroidal anti-inflammatory drugs via the β1 and β2 adrenergic receptors." | 1.37 | Effects of epinephrine and cortisol on the analgesic activity of metyrosine in rats. ( Akcay, F; Albayrak, Y; Karatay, S; Polat, B; Saglam, MB; Suleyman, H; Uslu, T; Yildirim, K, 2011) |
"Diagnosis of Tachon syndrome is made by elimination of the usual medical and surgical causes, and physicians performing local injections should be aware of this phenomenon." | 1.34 | An unusual complication of intra-articular injections of corticosteroids: Tachon syndrome. Two case reports. ( Hajjioui, A; Nys, A; Poiraudeau, S; Revel, M, 2007) |
"Pain was gradually intensified during her outpatient clinic and she was admitted." | 1.33 | [A case of fibromyalgia treated with medical and autogenic training]. ( Asama, Y; Goto, F; Nakai, K, 2005) |
"Sweet's syndrome is an uncommon acute skin disease, associated with a variety of medical problems." | 1.33 | Bortezomib-induced Sweet's syndrome. ( De Raeve, H; Lambert, J; Rombouts, S; Schroyens, W; Van de Velde, A; Van de Voorde, K; Van Regenmortel, N, 2005) |
"Hypogonadism has been established as a cause of osteoporosis in males, and in this case would explain the occurrence of fractures in the absence of other major risk factors." | 1.31 | Osteoporosis with underlying connective tissue disease: an unusual case. ( De Silva, M; Prasad, R, 2002) |
"In type I Gaucher's disease, episodes of severe disabling bone pain, the so called bone crises, may be resistant to all analgesics, including narcotics." | 1.29 | Effective treatment of painful bone crises in type I gaucher's disease with high dose prednisolone. ( Cohen, IJ; Katz, K; Kornreich, L; Mekhmandarov, S; Zaizov, R, 1996) |
"Prednisolone was dramatically effective in alleviating the myalgia as well as the other signs of panniculitis." | 1.28 | Myalgia as the major symptom in systemic panniculitis (Weber-Christian disease). ( Koh, CS; Ohara, S; Yanagisawa, N, 1992) |
"Eosinophilic fasciitis (EF) was diagnosed in a 23-year-old man presenting characteristic symptoms, skin changes, blood eosinophilia and typical histology showing thickened deep dermal fascia with inflammatory cells." | 1.28 | Compartment syndrome as a late complication of eosinophilic fasciitis. ( Fräki, J; Niskanen, L; Tahvanainen, K; Tulla, H, 1989) |
"A patient with ulcerative colitis presenting with vasculitic purpura is reported." | 1.27 | A case of ulcerative colitis presenting as vasculitic purpura. ( McCarthy, CF; McDermott, V, 1985) |
"Estramustine has been shown previously to be an effective drug in the treatment of metastatic prostatic cancer, demonstrating significant objective and subjective responses in long-term non-randomized trials and in other randomized trials." | 1.26 | The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation. ( Chu, TM; Gaeta, JF; Gibbons, RP; Johnson, DE; Loening, SA; Murphy, GP; Prout, GR; Saroff, J; Schmidt, JD; Scott, WW; Slack, N; Soloway, MS; Wajsman, Z, 1979) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 61 (38.13) | 18.7374 |
1990's | 16 (10.00) | 18.2507 |
2000's | 32 (20.00) | 29.6817 |
2010's | 37 (23.13) | 24.3611 |
2020's | 14 (8.75) | 2.80 |
Authors | Studies |
---|---|
Narupan, N | 1 |
Seeherunwong, A | 1 |
Pumpuang, W | 1 |
van der Meulen, C | 1 |
van de Stadt, LA | 2 |
Kroon, FPB | 2 |
Kortekaas, MC | 1 |
Boonen, AERCH | 1 |
Böhringer, S | 1 |
Niesters, M | 1 |
Reijnierse, M | 1 |
Rosendaal, FR | 1 |
Riyazi, N | 1 |
Starmans-Kool, M | 1 |
Turkstra, F | 1 |
van Zeben, J | 1 |
Allaart, CF | 1 |
Kloppenburg, M | 2 |
Thudium, CF | 1 |
Bay-Jensen, AC | 1 |
Saad, F | 1 |
Thiery-Vuillemin, A | 1 |
Wiechno, P | 1 |
Alekseev, B | 1 |
Sala, N | 1 |
Jones, R | 1 |
Kocak, I | 1 |
Chiuri, VE | 1 |
Jassem, J | 1 |
Fléchon, A | 1 |
Redfern, C | 1 |
Kang, J | 1 |
Burgents, J | 1 |
Gresty, C | 1 |
Degboe, A | 1 |
Clarke, NW | 1 |
Griffiths-Jones, DJ | 1 |
Garcia, YS | 1 |
Ryder, WD | 1 |
Pauling, JD | 1 |
Hall, F | 1 |
Lanyon, P | 1 |
Bhat, S | 1 |
Douglas, K | 1 |
Gunawardena, H | 1 |
Akil, M | 1 |
Anderson, M | 1 |
Griffiths, B | 1 |
Del Galdo, F | 1 |
Youssef, H | 1 |
Madhok, R | 1 |
Arthurs, B | 1 |
Buch, M | 1 |
Fligelstone, K | 1 |
Zubair, M | 1 |
Mason, JC | 1 |
Denton, CP | 1 |
Herrick, AL | 1 |
Hegde, V | 1 |
Shanmugasundaram, S | 1 |
Shaikh, S | 1 |
Kulkarni, V | 1 |
Suresh, N | 1 |
Setzer, FC | 1 |
Nagendrababu, V | 1 |
Witt, AM | 1 |
Kodal, LS | 1 |
Pedersen, BS | 1 |
Lund, EL | 1 |
Dysgaard, T | 1 |
Pisaniello, HL | 1 |
Lester, S | 1 |
Russell, O | 1 |
Black, R | 1 |
Tieu, J | 1 |
Richards, B | 1 |
Barrett, C | 1 |
Lassere, M | 1 |
March, L | 1 |
Buchbinder, R | 1 |
Whittle, SL | 1 |
Hill, CL | 1 |
Nattis, AS | 1 |
Rosenberg, ED | 1 |
Rasool, F | 1 |
Truthmann, J | 1 |
Freyer Martins Pereira, J | 1 |
Richter, A | 1 |
Schuster, F | 1 |
Witte, A | 1 |
Böhm, S | 1 |
Greser, A | 1 |
Kamin, P | 1 |
Stracke, S | 1 |
Dörr, M | 1 |
Bülow, R | 1 |
Engeli, S | 1 |
Gágyor, I | 1 |
Hummers, E | 1 |
Chenot, JF | 1 |
Zeng, J | 1 |
Jia, A | 1 |
Zhang, J | 1 |
Gao, B | 1 |
Xu, J | 1 |
Xing, Y | 1 |
Jing, X | 1 |
Jiao, Y | 1 |
Wang, J | 1 |
Xu, W | 1 |
Gao, L | 1 |
Shang, L | 1 |
Xu, S | 1 |
Tsunoda, K | 1 |
Endo, R | 1 |
El Hasbani, G | 1 |
Taher, AT | 1 |
Jawad, ASM | 1 |
Uthman, I | 1 |
Palacios Argueta, PJ | 1 |
Sánchez Rosenberg, GF | 1 |
Pineda, A | 1 |
McFarlane, M | 1 |
Azam, A | 1 |
Snead, D | 1 |
Disney, B | 1 |
Stevens, SL | 1 |
Schweitzer, D | 1 |
Efe, C | 1 |
Ozaslan, E | 1 |
Purnak, T | 1 |
Zhao, FC | 1 |
Guo, KJ | 1 |
Li, ZR | 1 |
Cheung, FY | 1 |
Leung, KC | 1 |
Ngan, RK | 1 |
Jindal, N | 1 |
Gaury, Y | 1 |
Banshiwal, RC | 1 |
Lamoria, R | 1 |
Bachhal, V | 1 |
Lisitsyna, TA | 1 |
Vel'tishchev, DIu | 1 |
Gerasimov, AN | 1 |
Seravina, OF | 1 |
Kovalevskaia, OB | 1 |
Zel'tyn', AE | 1 |
Novikov, AA | 1 |
Aleksandrova, EN | 1 |
Tallerova, AV | 1 |
Kovalenko, LP | 1 |
Birgens, H | 1 |
Frederiksen, H | 1 |
Hasselbalch, HC | 1 |
Rasmussen, IH | 1 |
Nielsen, OJ | 1 |
Kjeldsen, L | 1 |
Larsen, H | 1 |
Mourits-Andersen, T | 1 |
Plesner, T | 1 |
Rønnov-Jessen, D | 1 |
Vestergaard, H | 1 |
Klausen, TW | 1 |
Schöllkopf, C | 1 |
Cooper, AJ | 1 |
Powell, FC | 1 |
Tsuchida, M | 1 |
Fukushima, T | 1 |
Makino, K | 1 |
Miida, H | 1 |
Kuwabara, T | 1 |
Hafner, F | 1 |
Hackl, G | 1 |
Haas, E | 1 |
Eller, P | 1 |
Gstettner, C | 1 |
Vollmann, R | 1 |
Brodmann, M | 1 |
Stewart, BJ | 1 |
Majoni, SW | 1 |
Houssaini, GS | 1 |
Tahiri, L | 1 |
Ibrahimi, A | 1 |
Tizniti, S | 1 |
Elmrini, A | 1 |
Harzy, T | 1 |
Kajimoto, M | 1 |
Koga, M | 1 |
Narumi, H | 1 |
Inoue, H | 1 |
Matsushige, T | 1 |
Ohga, S | 1 |
Egsmose, EL | 1 |
Madsen, OR | 1 |
Inkpen, H | 1 |
Antunes, H | 1 |
Patraquim, C | 1 |
Baptista, V | 1 |
Silva Monteiro, L | 1 |
Griffin, J | 1 |
Potts, J | 1 |
Chatu, S | 1 |
Chung-Faye, G | 1 |
Rainer, TH | 1 |
Cheng, CH | 1 |
Janssens, HJ | 1 |
Man, CY | 1 |
Tam, LS | 1 |
Choi, YF | 1 |
Yau, WH | 1 |
Lee, KH | 1 |
Graham, CA | 1 |
Takaki, M | 1 |
Inozume, T | 1 |
Sano, S | 1 |
Mitsui, H | 1 |
Kawamura, T | 1 |
Shimada, S | 1 |
Chen, BN | 1 |
Denman, M | 1 |
Shoji, N | 1 |
Endo, Y | 1 |
Iikubo, M | 1 |
Ishii, T | 1 |
Harigae, H | 1 |
Aida, J | 1 |
Sakamoto, M | 1 |
Sasano, T | 1 |
Ribeiro, MI | 1 |
Cardoso, N | 1 |
Pires, S | 1 |
Veloso, T | 1 |
Barata, C | 1 |
Lu, CS | 1 |
Liu, JH | 1 |
Lange, JM | 1 |
Lundberg, GD | 1 |
MacIver, H | 1 |
Hordon, L | 1 |
Tay, E | 1 |
Gibson, A | 1 |
Chaudhary, N | 1 |
Olver, J | 1 |
Mochizuki, K | 1 |
Sawada, A | 1 |
Katsumura, N | 1 |
van Eijk, JJ | 1 |
van Alfen, N | 1 |
Berrevoets, M | 1 |
van der Wilt, GJ | 1 |
Pillen, S | 1 |
van Engelen, BG | 1 |
Nakajima, M | 1 |
Ueda, N | 1 |
Ohara, H | 1 |
Abe, M | 1 |
Kinoshita, M | 1 |
Berg, T | 1 |
Axelsson, S | 1 |
Engström, M | 1 |
Stjernquist-Desatnik, A | 1 |
Pitkäranta, A | 1 |
Kanerva, M | 1 |
Jonsson, L | 1 |
Valleala, H | 1 |
Korpela, M | 1 |
Möttönen, T | 1 |
Hienonen-Kempas, T | 1 |
Kauppi, M | 1 |
Hannonen, P | 1 |
Leirisalo-Repo, M | 1 |
Ohnuma, K | 1 |
Hosono, O | 1 |
Katayose, T | 1 |
Yoshikawa, N | 1 |
Kawasaki, H | 1 |
Fujii, T | 1 |
Oyaizu, N | 1 |
Tanaka, H | 1 |
Morimoto, C | 1 |
Femiano, F | 1 |
Buonaiuto, C | 1 |
Gombos, F | 1 |
Lanza, A | 1 |
Cirillo, N | 1 |
Elmantaser, M | 1 |
Stewart, G | 1 |
Young, D | 1 |
Duncan, R | 1 |
Gibson, B | 1 |
Ahmed, SF | 1 |
Gan, NY | 1 |
King, LL | 1 |
Teoh, SC | 1 |
Nagai, Y | 1 |
Igarashi, N | 1 |
Ishikawa, O | 1 |
Böttcher, A | 1 |
Guder, E | 1 |
Just, T | 1 |
Mehta, P | 1 |
Patel, L | 1 |
Roncaroli, F | 1 |
Pickering, MC | 1 |
Brand, A | 1 |
Albayrak, Y | 1 |
Saglam, MB | 1 |
Yildirim, K | 1 |
Karatay, S | 1 |
Polat, B | 1 |
Uslu, T | 1 |
Suleyman, H | 1 |
Akcay, F | 1 |
Karamouzian, S | 1 |
Nematollahi-Mahani, SN | 1 |
Nakhaee, N | 1 |
Eskandary, H | 1 |
Divala, T | 1 |
Rylance, J | 1 |
Prasad, R | 1 |
De Silva, M | 1 |
Rodriguez, N | 1 |
Eliott, D | 1 |
Garcia-Valenzuela, E | 1 |
Baker, J | 1 |
Ostör, AJ | 1 |
Hazleman, BL | 2 |
Horiguchi, A | 1 |
Uchida, A | 1 |
KOS, R | 1 |
VOTIN, J | 1 |
BUTTERWORTH, RF | 1 |
KAESER, HE | 1 |
LOCKE, RK | 1 |
STRAUSS, H | 1 |
BURROWS, FG | 1 |
Watanabe, T | 1 |
Abe, Y | 2 |
Hauswirth, AW | 1 |
Simonitsch-Klupp, I | 1 |
Uffmann, M | 1 |
Koller, E | 1 |
Sperr, WR | 1 |
Lechner, K | 1 |
Valent, P | 1 |
Rousseff, RT | 1 |
Simeonov, S | 1 |
Rexer, H | 1 |
Soylu, A | 1 |
Oztürk, Y | 1 |
Kasap, B | 1 |
Akman, N | 1 |
Türkmen, M | 1 |
Kavukçu, S | 1 |
Monzillo, PH | 1 |
Saab, VM | 1 |
Protti, GG | 1 |
Costa, AR | 1 |
Sanvito, WL | 1 |
Whitehouse, MW | 1 |
Goto, F | 1 |
Asama, Y | 1 |
Nakai, K | 1 |
Van Regenmortel, N | 1 |
Van de Voorde, K | 1 |
De Raeve, H | 1 |
Rombouts, S | 1 |
Van de Velde, A | 1 |
Lambert, J | 1 |
Schroyens, W | 1 |
Cohen, J | 1 |
Iwatani, M | 1 |
Inoue, E | 1 |
Nakamura, T | 1 |
Nakajima, A | 2 |
Hara, M | 1 |
Tomatsu, T | 1 |
Kamatani, N | 1 |
Yamanaka, H | 1 |
Medeiros, D | 1 |
Laufenberg, JA | 1 |
Miller, KL | 1 |
Buchanan, GR | 1 |
Saeidian, SR | 1 |
Hemmati, AA | 1 |
Haghighi, MH | 1 |
Hutchings, A | 1 |
Hollywood, J | 1 |
Lamping, DL | 1 |
Pease, CT | 1 |
Chakravarty, K | 1 |
Silverman, B | 1 |
Choy, EH | 1 |
Scott, DG | 1 |
Bourke, B | 1 |
Gendi, N | 1 |
Dasgupta, B | 1 |
Yanagisawa, S | 1 |
Inamori, M | 1 |
Endo, H | 1 |
Iida, H | 1 |
Akimoto, K | 1 |
Sakamoto, Y | 1 |
Akiyama, T | 1 |
Fujita, K | 1 |
Yoneda, M | 1 |
Takahashi, H | 1 |
Kobayashi, N | 1 |
Kirikoshi, H | 1 |
Kubota, K | 1 |
Ueno, N | 1 |
Song, YW | 1 |
Lee, EY | 1 |
Koh, EM | 1 |
Cha, HS | 1 |
Yoo, B | 1 |
Lee, CK | 1 |
Baek, HJ | 1 |
Kim, HA | 1 |
Suh, Y | 1 |
Kang, SW | 1 |
Lee, YJ | 1 |
Jung, HG | 1 |
Hajjioui, A | 1 |
Nys, A | 1 |
Poiraudeau, S | 1 |
Revel, M | 1 |
Sullivan, FM | 1 |
Swan, IR | 1 |
Donnan, PT | 1 |
Morrison, JM | 1 |
Smith, BH | 1 |
McKinstry, B | 1 |
Davenport, RJ | 1 |
Vale, LD | 1 |
Clarkson, JE | 1 |
Hammersley, V | 1 |
Hayavi, S | 1 |
McAteer, A | 1 |
Stewart, K | 1 |
Daly, F | 1 |
Hope-Simpson, RE | 1 |
Law, MR | 1 |
Hodson, ME | 1 |
Turner-Warwick, M | 1 |
Graf, D | 1 |
Engelhardt, D | 1 |
Permanetter, W | 1 |
Eide, N | 1 |
Skjeldal, O | 1 |
Mehta, BC | 1 |
Temin, PA | 1 |
Gerasimova, OI | 1 |
Mulley, GP | 1 |
Shiga, H | 1 |
Toda, T | 1 |
Ono, T | 1 |
Mochizuki, H | 1 |
Matsunaga, J | 1 |
Asano, S | 1 |
Cohen, IJ | 1 |
Kornreich, L | 1 |
Mekhmandarov, S | 1 |
Katz, K | 1 |
Zaizov, R | 1 |
Ganesan, V | 1 |
Lin, JP | 1 |
Chong, WK | 1 |
Kirkham, FJ | 1 |
Surtees, RA | 1 |
Gøtzsche, PC | 1 |
Johansen, HK | 1 |
Brincker, H | 1 |
Westin, J | 1 |
Abildgaard, N | 1 |
Gimsing, P | 1 |
Turesson, I | 1 |
Hedenus, M | 1 |
Ford, J | 1 |
Kandra, A | 1 |
Burnstein, Y | 1 |
Shelton, K | 1 |
Higginbotham, EJ | 1 |
Hickling, P | 1 |
Jacoby, RK | 1 |
Kirwan, JR | 1 |
Elstein, D | 1 |
Abrahamov, A | 1 |
Itzchaki, M | 1 |
Zimran, A | 1 |
Yoon, KH | 1 |
Ng, SC | 1 |
Distelrath, K | 1 |
Neuber, K | 1 |
Blödorn-Schlicht, N | 1 |
Altenhoff, J | 1 |
Dührsen, U | 1 |
Düring, J | 1 |
Steinkraus, V | 1 |
Haworth, CS | 1 |
Selby, PL | 1 |
Webb, AK | 1 |
Adams, JE | 1 |
Freemont, TJ | 1 |
Crawford, F | 1 |
Atkins, D | 1 |
Young, P | 1 |
Edwards, J | 1 |
Ishikawa, S | 1 |
Yahikozawa, H | 1 |
Yamazaki, M | 1 |
Kikkawa, M | 1 |
Ikeda, S | 1 |
Hanyu, N | 1 |
Hannerz, J | 1 |
Kaneko, K | 1 |
Matsumura, K | 1 |
Maruyama, Y | 1 |
Vitali, N | 1 |
Tondeur, M | 1 |
Hermans, P | 1 |
Deweerdt, S | 1 |
Clumeck, N | 1 |
Diamond, D | 1 |
Fisher, B | 1 |
Martins, JK | 1 |
Roedl, EA | 1 |
Dornan, TL | 1 |
Espir, ML | 1 |
Gale, EA | 1 |
Tattersall, RB | 1 |
Worthington, BS | 1 |
Murphy, GP | 1 |
Gibbons, RP | 1 |
Johnson, DE | 1 |
Prout, GR | 1 |
Schmidt, JD | 1 |
Soloway, MS | 1 |
Loening, SA | 1 |
Chu, TM | 1 |
Gaeta, JF | 1 |
Saroff, J | 1 |
Wajsman, Z | 1 |
Slack, N | 1 |
Scott, WW | 1 |
Murthy, MH | 1 |
Rhymer, AR | 1 |
Wright, V | 1 |
Caci, F | 1 |
Gluck, GM | 1 |
Rowan, RM | 1 |
Kuzuna, S | 1 |
Kawai, K | 1 |
Miyaishi, N | 1 |
Fowler, TJ | 1 |
Earl, CJ | 1 |
McAllister, VL | 1 |
McDonald, WI | 1 |
Ohara, S | 1 |
Koh, CS | 1 |
Yanagisawa, N | 1 |
Senff, H | 1 |
Köllner, A | 1 |
Engelmann, L | 1 |
Woort-Menker, M | 1 |
Mensing, H | 1 |
Kunze, J | 1 |
Marks, R | 1 |
Knopf, HL | 1 |
Ralphs, JR | 1 |
Stamp, TC | 1 |
Dopping-Hepenstal, PJ | 1 |
Ali, SY | 1 |
Niskanen, L | 1 |
Tulla, H | 1 |
Fräki, J | 1 |
Tahvanainen, K | 1 |
Gekht, BM | 1 |
Kolomenskaia, EA | 1 |
Shagal, DI | 1 |
Merkulova, DM | 1 |
Ibragimova, GV | 1 |
Levine, JD | 1 |
Lam, D | 1 |
Taiwo, YO | 1 |
Donatoni, P | 1 |
Goetzl, EJ | 1 |
Powell-Tuck, J | 1 |
MacRae, KD | 1 |
Healy, MJ | 1 |
Lennard-Jones, JE | 1 |
Parkins, RA | 1 |
Ogura, T | 1 |
Hirakawa, S | 1 |
Suzuki, S | 1 |
Ota, Z | 1 |
Togawa, T | 1 |
Nogami, I | 1 |
Maigne, R | 1 |
Maigne, JY | 1 |
Setdikov, RA | 1 |
Tabuchi, Y | 1 |
Ogihara, T | 1 |
Fukuchi, K | 1 |
Seto, T | 1 |
Kumahara, Y | 1 |
Nakamaru, O | 1 |
Ochiai, J | 1 |
Kanaide, H | 1 |
Okamatsu, S | 1 |
Yamada, A | 1 |
Nakamura, M | 1 |
Greenstone, M | 1 |
Shaw, AB | 1 |
McDermott, V | 1 |
McCarthy, CF | 1 |
Tumen, HJ | 1 |
Warren, KW | 1 |
Braasch, JW | 1 |
Thum, CW | 1 |
Brodthagen, H | 1 |
Larsen, V | 1 |
Brockner, J | 1 |
Amris, CJ | 1 |
Huss, V | 1 |
Tönnis, D | 1 |
Hördegen, K | 1 |
Bär, HW | 1 |
Ginsburg, BE | 1 |
Wasserman, J | 1 |
Huldt, G | 1 |
Bergstrand, A | 1 |
Jasani, MK | 3 |
Downie, WW | 1 |
Samuels, BM | 1 |
Buchanan, WW | 3 |
Mullanney, PJ | 1 |
Malpas, JS | 1 |
Tempo, B | 1 |
Grosso, E | 1 |
Tibaldi, GP | 1 |
Fiorucci, GC | 1 |
Perry, BD | 1 |
Bracegirdle, JR | 1 |
Ghosh, SK | 1 |
Reddy, TA | 1 |
Ritchie, DM | 1 |
Boyle, JA | 2 |
McInnes, JM | 2 |
Dalakos, TG | 2 |
Grieveson, P | 2 |
Schoger, GA | 1 |
Ritchie, DA | 1 |
Tronstad, L | 1 |
Kitridou, RC | 1 |
Solomon, SD | 1 |
Mathew, NT | 1 |
Chandy, J | 1 |
Grimmeisen, H | 1 |
Krahl, H | 1 |
Iio, M | 1 |
Sandler, SG | 1 |
Tobin, W | 1 |
Henderson, ES | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase II Study to Compare the Efficacy, Safety and Tolerability of Olaparib Versus Placebo When Given in Addition to Abiraterone Treatment in Patients With Metastatic Castrate-Resistant Prostate [NCT01972217] | Phase 2 | 158 participants (Actual) | Interventional | 2014-04-01 | Completed | ||
Eccentric Exercise in Epicondylitis: Direct Application By Physical Therapist Vs Self-Application By Patient[NCT03996928] | 20 participants (Anticipated) | Interventional | 2017-01-01 | Recruiting | |||
Treatment of Intractable Common Extensor Tendon Injury Using Allogeneic Adipose-derived Mesenchymal Stem Cells (Allo-ASC): a Phase II Randomized Controlled Trial[NCT03449082] | Phase 2 | 30 participants (Actual) | Interventional | 2018-05-04 | Active, not recruiting | ||
Sirolimus in the Treatment of Refractory/Relapsed Warm Autoimmune Hemolytic Anemia (AIHA): a Phase 2 Prospective Trial[NCT05925023] | Phase 2 | 22 participants (Anticipated) | Interventional | 2023-06-24 | Recruiting | ||
Zanubrutinib in Relapsed or Refractory Warm Autoimmune Hemolytic Anemia: a Prospective Cohort Study[NCT05922839] | Phase 2 | 22 participants (Anticipated) | Interventional | 2023-06-30 | Not yet recruiting | ||
The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune Antibody Mediated Hemolytic Anemia[NCT05004259] | Phase 1 | 10 participants (Anticipated) | Interventional | 2022-03-21 | Recruiting | ||
Autologous Transplantation of Bone Marrow Mesenchymal Stem Cells in Patients of Spinal Cord Injury-Phase I Clinical Trial[NCT02482194] | Phase 1 | 9 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
Is There Any Advantage of PRP Over Autologous Blood Injection in the Treatment of Chronic Plantar Fasciitis? A Prospective Randomized Double Blinded Study[NCT05240872] | Phase 3 | 60 participants (Actual) | Interventional | 2020-03-01 | Completed | ||
A Study Into the Use of Prefabricated Orthotics in Shoes, in Combination With Using Indoor Comfort Sandals With built-in Arch Support vs. the Sole Use of Prefabricated Orthotics in Shoes Alone, for the Treatment of Plantar Fasciitis. A Randomised Control [NCT04894383] | 104 participants (Actual) | Interventional | 2021-07-23 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"DLTs were assessed by a Safety Review Committee (SRC) after a minimum of 3 patients had received at least 14 days of treatment in Part A.~A DLT was defined as any toxicity which was not a recognised AE of abiraterone or prednisolone, and was not attributable to the disease or disease-related processes under investigation, which occurred during a minimum period of 14 days treatment and which included: 1. haematological toxicity CTCAE v4.0 Grade 4 or higher present for more than 4 days (except anaemia); 2. non-haematological toxicity CTCAE v4.0 Grade 3 or higher including infection, corrected QT interval prolongation; 3. any other toxicity that was greater than that at baseline, was clinically significant and/or unacceptable, did not respond to supportive care, resulted in a disruption of dosing schedule of 7 days or more, or was judged to be a DLT by the SRC.~A DLT excluded alopecia and isolated laboratory changes of any grade without clinical sequelae or clinical significance." (NCT01972217)
Timeframe: From Day 1 for Cohort 1 and from Day 4 for Cohort 2 up to 14 days treatment with olaparib + abiraterone for 3 patients.
Intervention | Patients (Number) |
---|---|
Part A Cohort 1: Olaparib 200 mg + Abiraterone | 2 |
Part A Cohort 2: Olaparib 300 mg + Abiraterone | 4 |
"The median best percentage change from baseline in CTC levels was determined to assess the anti-tumour activity of olaparib when given in combination with abiraterone, compared with placebo given in addition to abiraterone.~The best percentage change was defined as the biggest CTC level reduction compared with baseline or smallest increase in the absence of a decrease." (NCT01972217)
Timeframe: From baseline, then every 4 weeks up to Week 24, and then every 12 weeks.
Intervention | Percentage change in CTC level (Median) |
---|---|
Part B: Olaparib + Abiraterone | -1.0 |
Part B: Placebo + Abiraterone | -1.0 |
"The best percentage change from baseline in PSA levels was determined to assess the anti-tumour activity of olaparib when given in addition to abiraterone, compared with placebo given in addition to abiraterone.~The best percentage change was defined as the biggest reduction in PSA level compared with baseline or smallest increase in the absence of a decrease." (NCT01972217)
Timeframe: From baseline, then every 4 weeks up to Week 52, and then every 12 weeks.
Intervention | Percentage change in PSA level (Median) |
---|---|
Part B: Olaparib + Abiraterone | -54.16 |
Part B: Placebo + Abiraterone | -49.85 |
"OS was determined to assess the efficacy of olaparib when given in addition to abiraterone, compared with placebo given in addition to abiraterone.~OS was performed at the time of the analysis of rPFS, and the median OS, calculated using the Kaplan-Meier technique, is presented." (NCT01972217)
Timeframe: From baseline, every 12 weeks up to Week 72, then every 24 weeks up to 24 months.
Intervention | Months (Median) |
---|---|
Part B: Olaparib + Abiraterone | 22.7 |
Part B: Placebo + Abiraterone | 20.9 |
"The efficacy of olaparib when given in combination with abiraterone was assessed by rPFS, defined as the time from randomisation to disease progression using Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (for soft tissue disease) and Prostate Cancer Working Group 2 (PCWG-2) (for bone disease) criteria, or death.~Progression using RECIST 1.1 criteria was defined as at least 20% increase from baseline in the sum of diameters of target lesions, progression of existing non-target lesions, or the appearance of at least 1 new lesion.~Progression using PCWG-2 criteria was determined if 2 or more new metastatic bone lesions were observed (with a total of at least 4 new lesions since baseline assessment if observed at the 12 week scan, or persistence of or increase in number of lesions if observed after the 12 week scan as determined by a confirmatory scan at least 6 weeks later or at next scheduled visit)." (NCT01972217)
Timeframe: From baseline, every 12 weeks up to Week 72, then every 24 weeks up to 24 months.
Intervention | Months (Median) |
---|---|
Part B: Olaparib + Abiraterone | 13.8 |
Part B: Placebo + Abiraterone | 8.2 |
The efficacy of olaparib when given in combination with abiraterone was assessed by PFS2, defined by local standard clinical practice and included objective radiological progression by RECIST 1.1 (soft tissue), symptomatic progression, rise in PSA level or death in the absence of overall progression. (NCT01972217)
Timeframe: From randomisation until analysis cut-off date (up to approximately 3 years).
Intervention | Months (Median) |
---|---|
Part B: Olaparib + Abiraterone | 23.3 |
Part B: Placebo + Abiraterone | 18.5 |
"The overall radiological ORR was calculated to assess the anti-tumour activity of olaparib in combination with abiraterone, compared with placebo in combination with abiraterone.~The best overall ORR was defined as the percentage of patients with at least 1 visit response of complete response (CR) or partial response (PR) in soft tissue disease assessed by RECIST 1.1 and also bone scan status of non-progressive disease or non-evaluable for their bone scans assessed by PCWG-2.~CR: Disappearance of all target lesions. Reduction of pathological lymph nodes to <10 millimetres.~PR: At least a 30% decrease in the sum of diameters of target lesions from baseline.~The percentage of patients with a response is presented." (NCT01972217)
Timeframe: From baseline, then every 4 weeks up to Week 52, and then every 12 weeks.
Intervention | Percentage of patients (Number) |
---|---|
Part B: Olaparib + Abiraterone | 27.3 |
Part B: Placebo + Abiraterone | 31.6 |
"The efficacy of olaparib when given in combination with abiraterone was assessed by rPFS, defined as the time from randomisation to disease progression using RECIST version 1.1 (for soft tissue disease) and PCWG-2 (for bone disease) criteria, or death.~Progression using RECIST 1.1 criteria was defined as at least 20% increase from baseline in the sum of diameters of target lesions, progression of existing non-target lesions, or the appearance of at least 1 new lesion.~Progression using PCWG-2 criteria was determined if 2 or more new metastatic bone lesions were observed (with a total of at least 4 new lesions since baseline assessment if observed at the 12 week scan, or persistence of or increase in number of lesions if observed after the 12 week scan as determined by a confirmatory scan at least 6 weeks later or at next scheduled visit).~The percentage of patients with progression events is presented overall and according to RECIST 1.1 and/or PCWG-2 criteria, or death." (NCT01972217)
Timeframe: From baseline, every 12 weeks up to Week 72, then every 24 weeks up to 24 months.
Intervention | Percentage of patients (Number) |
---|---|
Part B: Olaparib + Abiraterone | 64.8 |
Part B: Placebo + Abiraterone | 76.1 |
"The TFST and TSST were determined to assess the anti-tumour activity of olaparib when given in combination with abiraterone, compared with placebo given in addition to abiraterone.~TFST was defined as the time from randomisation to the earlier of first subsequent anti-cancer therapy start date following study treatment discontinuation, or death.~TSST was defined as the time from randomisation to the earlier of the second subsequent anti-cancer therapy start date following study treatment discontinuation, or death." (NCT01972217)
Timeframe: From randomisation until analysis cut-off date (up to approximately 3 years).
Intervention | Months (Median) | |
---|---|---|
TFST | TSST | |
Part B: Olaparib + Abiraterone | 13.5 | 19.6 |
Part B: Placebo + Abiraterone | 9.7 | 18.0 |
"Following multiple dosing to steady state of olaparib 300 mg bid, the Cohort 2 olaparib Cmax,ss is presented for olaparib monotherapy and for olaparib given in combination with abiraterone.~Only patients with data available for analysis at each time point are presented." (NCT01972217)
Timeframe: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
Intervention | micrograms per millilitre (mcg/mL) (Geometric Mean) |
---|---|
Olaparib + abiraterone | |
Part A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone | 7.724 |
"Following multiple dosing to steady state of olaparib 300 mg bid, the Cohort 2 olaparib Cmax,ss is presented for olaparib monotherapy and for olaparib given in combination with abiraterone.~Only patients with data available for analysis at each time point are presented." (NCT01972217)
Timeframe: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
Intervention | micrograms per millilitre (mcg/mL) (Geometric Mean) | |
---|---|---|
Olaparib alone | Olaparib + abiraterone | |
Part A Cohort 2 Group 1: Olaparib, Olaparib + Abiraterone | 7.781 | 6.504 |
"Following multiple dosing to steady state of olaparib 300 mg bid, the Cohort 2 olaparib AUCss is presented for olaparib monotherapy and for olaparib given in combination with abiraterone.~Only patients with data available for analysis at each time point are presented." (NCT01972217)
Timeframe: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
Intervention | mcg*h/mL (Geometric Mean) |
---|---|
Olaparib + abiraterone | |
Part A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone | 49.51 |
"Following multiple dosing to steady state of olaparib 300 mg bid, the Cohort 2 olaparib AUCss is presented for olaparib monotherapy and for olaparib given in combination with abiraterone.~Only patients with data available for analysis at each time point are presented." (NCT01972217)
Timeframe: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
Intervention | mcg*h/mL (Geometric Mean) | |
---|---|---|
Olaparib alone | Olaparib + abiraterone | |
Part A Cohort 2 Group 1: Olaparib, Olaparib + Abiraterone | 45.27 | 40.83 |
"Following multiple dosing to steady state of olaparib 300 mg bid, the Cohort 2 olaparib Cmin,ss is presented for olaparib monotherapy and for olaparib given in combination with abiraterone.~Only patients with data available for analysis at each time point are presented." (NCT01972217)
Timeframe: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
Intervention | mcg/mL (Geometric Mean) |
---|---|
Olaparib + abiraterone | |
Part A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone | 1.279 |
"Following multiple dosing to steady state of olaparib 300 mg bid, the Cohort 2 olaparib Cmin,ss is presented for olaparib monotherapy and for olaparib given in combination with abiraterone.~Only patients with data available for analysis at each time point are presented." (NCT01972217)
Timeframe: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
Intervention | mcg/mL (Geometric Mean) | |
---|---|---|
Olaparib alone | Olaparib + abiraterone | |
Part A Cohort 2 Group 1: Olaparib, Olaparib + Abiraterone | 1.264 | 0.9170 |
"Following multiple dosing to steady state of olaparib 300 mg bid, the Cohort 2 olaparib tmax,ss is presented for olaparib monotherapy and for olaparib given in combination with abiraterone.~Only patients with data available for analysis at each time point are presented." (NCT01972217)
Timeframe: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
Intervention | Hours (h) (Median) |
---|---|
Olaparib + abiraterone | |
Part A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone | 2.000 |
"Following multiple dosing to steady state of olaparib 300 mg bid, the Cohort 2 olaparib tmax,ss is presented for olaparib monotherapy and for olaparib given in combination with abiraterone.~Only patients with data available for analysis at each time point are presented." (NCT01972217)
Timeframe: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
Intervention | Hours (h) (Median) | |
---|---|---|
Olaparib alone | Olaparib + abiraterone | |
Part A Cohort 2 Group 1: Olaparib, Olaparib + Abiraterone | 2.000 | 2.080 |
"Following multiple dosing to steady state of abiraterone 1000 mg once daily, the Cohort 2 abiraterone AUCss is presented for abiraterone monotherapy and for olaparib given in combination with abiraterone.~Only patients with data available for analysis at each time point are presented." (NCT01972217)
Timeframe: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
Intervention | ng*h/mL (Geometric Mean) |
---|---|
Olaparib + abiraterone | |
Part A Cohort 2 Group 1: Olaparib, Olaparib + Abiraterone | 718.9 |
"Following multiple dosing to steady state of abiraterone 1000 mg once daily, the Cohort 2 abiraterone AUCss is presented for abiraterone monotherapy and for olaparib given in combination with abiraterone.~Only patients with data available for analysis at each time point are presented." (NCT01972217)
Timeframe: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
Intervention | ng*h/mL (Geometric Mean) | |
---|---|---|
Abiraterone alone | Olaparib + abiraterone | |
Part A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone | 825.5 | 524.6 |
"Following multiple dosing to steady state of abiraterone 1000 mg once daily, the Cohort 2 abiraterone Cmax,ss is presented for abiraterone monotherapy and for olaparib given in combination with abiraterone.~Only patients with data available for analysis at each time point are presented." (NCT01972217)
Timeframe: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
Intervention | nanograms per millilitre (ng/mL) (Geometric Mean) |
---|---|
Olaparib + abiraterone | |
Part A Cohort 2 Group 1: Olaparib, Olaparib + Abiraterone | 130.7 |
"Following multiple dosing to steady state of abiraterone 1000 mg once daily, the Cohort 2 abiraterone Cmax,ss is presented for abiraterone monotherapy and for olaparib given in combination with abiraterone.~Only patients with data available for analysis at each time point are presented." (NCT01972217)
Timeframe: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
Intervention | nanograms per millilitre (ng/mL) (Geometric Mean) | |
---|---|---|
Abiraterone alone | Olaparib + abiraterone | |
Part A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone | 145.8 | 86.12 |
"Following multiple dosing to steady state of abiraterone 1000 mg once daily, the Cohort 2 abiraterone Cmin,ss is presented for abiraterone monotherapy and for olaparib given in combination with abiraterone.~Only patients with data available for analysis at each time point are presented." (NCT01972217)
Timeframe: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
Intervention | ng/mL (Geometric Mean) |
---|---|
Olaparib + abiraterone | |
Part A Cohort 2 Group 1: Olaparib, Olaparib + Abiraterone | 7.983 |
"Following multiple dosing to steady state of abiraterone 1000 mg once daily, the Cohort 2 abiraterone Cmin,ss is presented for abiraterone monotherapy and for olaparib given in combination with abiraterone.~Only patients with data available for analysis at each time point are presented." (NCT01972217)
Timeframe: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
Intervention | ng/mL (Geometric Mean) | |
---|---|---|
Abiraterone alone | Olaparib + abiraterone | |
Part A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone | 8.376 | 6.358 |
"Following multiple dosing to steady state of abiraterone 1000 mg once daily, the Cohort 2 abiraterone tmax,ss is presented for abiraterone monotherapy and for olaparib given in combination with abiraterone.~Only patients with data available for analysis at each time point are presented." (NCT01972217)
Timeframe: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
Intervention | Hours (Median) |
---|---|
Olaparib + abiraterone | |
Part A Cohort 2 Group 1: Olaparib, Olaparib + Abiraterone | 3.000 |
"Following multiple dosing to steady state of abiraterone 1000 mg once daily, the Cohort 2 abiraterone tmax,ss is presented for abiraterone monotherapy and for olaparib given in combination with abiraterone.~Only patients with data available for analysis at each time point are presented." (NCT01972217)
Timeframe: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.
Intervention | Hours (Median) | |
---|---|---|
Abiraterone alone | Olaparib + abiraterone | |
Part A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone | 2.525 | 2.500 |
"The safety and tolerability of olaparib in combination with abiraterone was assessed during Part A of the study. The percentage of patients experiencing AEs, including information on seriousness, severity, study treatment relationship and those leading to discontinuation for all doses of olaparib and for abiraterone are presented.~Severity of AEs was assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse events (CTCAE) v4.0. AEs were assigned to a Grade from 1 through 5 as follows:~Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life-threatening requiring hospitalisation; Grade 4: Life-threatening consequences; Grade 5: Death related to AE.~'c-r' = causally related 'discont' = discontinuation." (NCT01972217)
Timeframe: Cohort 1 and 2: From baseline in Part A (Day 1 for each cohort) up to 30 days following last dose of study treatment.
Intervention | Percentage of patients (Number) | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Any AE c-r to olaparib + abiraterone | Any AE c-r to olaparib only | Any AE c-r to abiraterone only | Any AE CTCAE Grade 3 or higher | Any AE CTCAE Grade 3 or higher c-r to olaparib | Any AE CTCAE Grade 3 or higher c-r to abiraterone | Any AE with outcome = death | Any serious AE (SAE) | Any SAE c-r to olaparib | Any SAE c-r to abiraterone | Any AE causing discont of olaparib | Any AE causing discont of olaparib c-r to olaparib | Any AE causing discont olaparib c-r to abiraterone | |
Part A Cohort 1: Olaparib 200 mg + Abiraterone | 66.7 | 33.3 | 0 | 66.7 | 0 | 0 | 0 | 66.7 | 0 | 0 | 0 | 0 | 0 |
Part A Cohort 2: Olaparib 300 mg + Abiraterone | 46.2 | 7.7 | 15.4 | 23.1 | 7.7 | 7.7 | 0 | 23.1 | 0 | 0 | 7.7 | 0 | 0 |
"The safety and tolerability of olaparib when given in combination with abiraterone was assessed during Part B of the study. The percentage of patients experiencing AEs, including information on seriousness, severity, study treatment relationship and those leading to discontinuation for all doses of olaparib and for abiraterone are presented.~Severity of AEs was assessed using the NCI Common Terminology CTCAE v4.0. AEs were assigned to a Grade from 1 through 5 as follows:~Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life-threatening requiring hospitalisation; Grade 4: Life-threatening consequences; Grade 5: Death related to AE.~'c-r' = causally related. 'discont' = discontinuation. 'ola/pla' = olaparib/placebo." (NCT01972217)
Timeframe: From first dose of study treatment following randomisation in Part B up to 30 days following last dose of study treatment (up to approximately 3 years).
Intervention | Percentage of patients (Number) | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Any AE c-r to ola/pla + abiraterone | Any AE c-r to ola/pla only | Any AE c-r to abiraterone only | Any AE CTCAE Grade 3 or higher | Any AE CTCAE Grade 3 or higher c-r to ola/pla | Any AE CTCAE Grade 3 or higher c-r to abiraterone | Any AE with outcome = death | Any AE with outcome = death c-r to ola/pla | Any AE with outcome = death c-r to abiraterone | Any SAE | Any SAE c-r to ola/pla | Any SAE c-r to abiraterone | Any AE causing discont of ola/pla | Any AE causing discont of treatment c-r to ola/pla | Any AE causing discont treatment c-r abiraterone | |
Part B: Olaparib + Abiraterone | 45.1 | 18.3 | 1.4 | 53.5 | 23.9 | 16.9 | 5.6 | 1.4 | 0 | 35.2 | 9.9 | 5.6 | 29.6 | 16.9 | 8.5 |
Part B: Placebo + Abiraterone | 12.7 | 9.9 | 7.0 | 28.2 | 5.6 | 1.4 | 1.4 | 0 | 0 | 19.7 | 1.4 | 0 | 9.9 | 5.6 | 1.4 |
"The percentages of patients with single visit responses and with confirmed responses are presented to assess the anti-tumour activity of olaparib when given in addition to abiraterone, compared with placebo given in addition to abiraterone.~A single visit response was defined as any post-dose visit PSA level reduced by 50% or more compared with baseline.~A confirmed response was defined as a reduction in PSA level of 50% or more on 2 consecutive occasions at least 4 weeks apart compared with baseline.~Patients may have had more than 1 single visit response or confirmed response but were counted once." (NCT01972217)
Timeframe: From baseline, then every 4 weeks up to Week 24, and then every 12 weeks.
Intervention | Percentage of patients (Number) | |
---|---|---|
Single visit response | Confirmed response | |
Part B: Olaparib + Abiraterone | 50.7 | 47.9 |
Part B: Placebo + Abiraterone | 47.9 | 42.3 |
11 reviews available for prednisolone and Ache
Article | Year |
---|---|
Post-partum eosinophilic gastroenteritis: A case report.
Topics: Adult; Anti-Inflammatory Agents; Ascites; Biopsy; Endoscopy, Digestive System; Enteritis; Eosinophil | 2018 |
Idiopathic orbital inflammation with extensive intra- and extracranial extension presenting as 6th nerve palsy--a case report and literature review.
Topics: Abducens Nerve Diseases; Adolescent; Blindness; Diplopia; Drug Therapy, Combination; Headache; Human | 2008 |
Managing the patient with polymyalgia.
Topics: Aged; Anti-Inflammatory Agents; Diagnosis, Differential; Giant Cell Arteritis; Humans; Incidence; Mi | 2002 |
Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature.
Topics: Adult; Bone Marrow; Disease Progression; Drug Evaluation; Drug Therapy, Combination; Female; Fever; | 2004 |
[Steroid myopathies (review)].
Topics: Adolescent; Adrenocortical Hyperfunction; Adult; Aged; Animals; Child; Child, Preschool; Cortisone; | 1980 |
Meta-analysis of short-term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis.
Topics: Administration, Oral; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, | 1998 |
[Polymyositis associated with HIV immunodeficiency: clinical case and literature review].
Topics: Adult; Anti-Inflammatory Agents; Biopsy; Deglutition Disorders; Diagnosis, Differential; Female; HIV | 2001 |
Pancreatic cancer.
Topics: Abdomen; Biopsy; Carcinoma, Intraductal, Noninfiltrating; Celiac Disease; Cholecystokinin; Diabetes | 1975 |
Diagnosis and surgical treatment of carcinoma of the pancreas.
Topics: Adenocarcinoma; Anorexia Nervosa; Body Weight; Constipation; Diabetes Mellitus; Diagnosis, Different | 1968 |
[Glucocorticoid preparations in the therapy of pulpitis].
Topics: Animals; Anti-Bacterial Agents; Chloramphenicol; Diagnosis, Differential; Follow-Up Studies; Glucoco | 1971 |
The patient with rheumatoid arthritis.
Topics: Activities of Daily Living; Arthritis, Rheumatoid; Bursitis; Chloroquine; Diagnosis, Differential; F | 1971 |
31 trials available for prednisolone and Ache
Article | Year |
---|---|
Neuropathic-like pain symptoms in inflammatory hand osteoarthritis lower quality of life and may not decrease under prednisolone treatment.
Topics: Female; Humans; Male; Middle Aged; Osteoarthritis, Knee; Pain; Pain Measurement; Peripheral Nervous | 2022 |
Serum biomarkers in prednisolone-treated hand osteoarthritis patients.
Topics: Biomarkers; C-Reactive Protein; Female; Humans; Male; Middle Aged; Osteoarthritis; Pain; Prednisolon | 2023 |
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
Topics: Androgen Antagonists; Androgens; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Doceta | 2022 |
A Phase II randomized controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS).
Topics: COVID-19; Double-Blind Method; Humans; Pain; Pandemics; Prednisolone; Scleroderma, Diffuse; Treatmen | 2023 |
Effect of Preoperative Oral Steroids in Comparison to Anti-inflammatory on Anesthetic Success of Inferior Alveolar Nerve Block in Mandibular Molars with Symptomatic Irreversible Pulpitis-A Double-blinded Randomized Clinical Trial.
Topics: Anesthesia, Dental; Anesthetics, Local; Anti-Inflammatory Agents; Dexamethasone; Double-Blind Method | 2023 |
Intracanalicular dexamethasone insert for post-corneal crosslinking inflammation and pain: the LINK study.
Topics: Cross-Linking Reagents; Dexamethasone; Epithelium, Corneal; Humans; Inflammation; Keratoconus; Ophth | 2023 |
Prednisolone Versus Colchicine for Acute Gout in Primary Care (COPAGO): protocol for a two-arm multicentre, pragmatic, prospective, randomized, double-blind, controlled clinical trial of prednisolone and colchicine for non-inferiority with a parallel grou
Topics: Adult; Arthritis, Gouty; Colchicine; Double-Blind Method; Gout; Humans; Multicenter Studies as Topic | 2023 |
Comparison of the therapeutic effects of 15 mg and 30 mg initial daily prednisolone doses in patients with subacute thyroiditis: a multicenter, randomized, open-label, parallel-controlled trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Humans; Hypothyroidism; Pain; Prednisolone; Thyroidi | 2023 |
Comparison of short term results of single injection of autologous blood and steroid injection in tennis elbow: a prospective study.
Topics: Adult; Blood Transfusion, Autologous; Female; Glucocorticoids; Humans; Injections, Intra-Articular; | 2013 |
Comparison of short term results of single injection of autologous blood and steroid injection in tennis elbow: a prospective study.
Topics: Adult; Blood Transfusion, Autologous; Female; Glucocorticoids; Humans; Injections, Intra-Articular; | 2013 |
Comparison of short term results of single injection of autologous blood and steroid injection in tennis elbow: a prospective study.
Topics: Adult; Blood Transfusion, Autologous; Female; Glucocorticoids; Humans; Injections, Intra-Articular; | 2013 |
Comparison of short term results of single injection of autologous blood and steroid injection in tennis elbow: a prospective study.
Topics: Adult; Blood Transfusion, Autologous; Female; Glucocorticoids; Humans; Injections, Intra-Articular; | 2013 |
A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derive | 2013 |
A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derive | 2013 |
A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derive | 2013 |
A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derive | 2013 |
A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derive | 2013 |
A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derive | 2013 |
A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derive | 2013 |
A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derive | 2013 |
A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derive | 2013 |
Oral Prednisolone in the Treatment of Acute Gout: A Pragmatic, Multicenter, Double-Blind, Randomized Trial.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Doubl | 2016 |
A comparative study of the effects of bucillamine and salazosulfapyridine in the treatment of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Cysteine; Drug Therapy, Combination | 2009 |
The course of pain in Bell's palsy: treatment with prednisolone and valacyclovir.
Topics: Acyclovir; Adult; Anti-Inflammatory Agents; Antiviral Agents; Bell Palsy; Double-Blind Method; Earac | 2009 |
Pilot study on recurrent aphthous stomatitis (RAS): a randomized placebo-controlled trial for the comparative therapeutic effects of systemic prednisone and systemic montelukast in subjects unresponsive to topical therapy.
Topics: Acetates; Adolescent; Adult; Cyclopropanes; Double-Blind Method; Female; Glucocorticoids; Humans; Le | 2010 |
Clinical safety and primary efficacy of bone marrow mesenchymal cell transplantation in subacute spinal cord injured patients.
Topics: Adult; Anti-Inflammatory Agents; Bone Marrow Transplantation; Cell Differentiation; Female; Follow-U | 2012 |
Efficacy profile of bucillamine in rheumatoid arthritis patients in a large observational cohort study, IORRA.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cohort Studies; Cysteine; Drug Thera | 2006 |
Short-term oral corticosteroid therapy for acute haemarthrosis in haemophilia patients with high-titre inhibitors.
Topics: Adolescent; Adult; Blood Coagulation Factor Inhibitors; Blood Coagulation Factors; Child; Child, Pre | 2007 |
Pain relieving effect of short-course, pulse prednisolone in managing frozen shoulder.
Topics: Adult; Aged; Anti-Inflammatory Agents; Bursitis; Diclofenac; Female; Humans; Male; Middle Aged; Pain | 2007 |
Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Blood Sedimentation; Female; Health Status; Human | 2007 |
Assessment of comparative pain relief and tolerability of SKI306X compared with celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, double-dummy, phase III, noninferiority clinical trial.
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Clematis; Cyclooxy | 2007 |
Early treatment with prednisolone or acyclovir in Bell's palsy.
Topics: Acyclovir; Adult; Antiviral Agents; Bell Palsy; Double-Blind Method; Drug Therapy, Combination; Faci | 2007 |
Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols | 1998 |
Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Finger Joi | 1998 |
Steroid injection for heel pain: evidence of short-term effectiveness. A randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anesthetics, Local; Double-Blind Method; Fasciitis; Female; Foot Dis | 1999 |
Steroid injection for heel pain: evidence of short-term effectiveness. A randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anesthetics, Local; Double-Blind Method; Fasciitis; Female; Foot Dis | 1999 |
Steroid injection for heel pain: evidence of short-term effectiveness. A randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anesthetics, Local; Double-Blind Method; Fasciitis; Female; Foot Dis | 1999 |
Steroid injection for heel pain: evidence of short-term effectiveness. A randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anesthetics, Local; Double-Blind Method; Fasciitis; Female; Foot Dis | 1999 |
Indomethacin or prednisolone at night in rheumatoid arthritis?
Topics: Adult; Aged; Analgesics; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; | 1978 |
Double-blind study of prednisolone and papase as inhibitors of complications after oral surgery.
Topics: Clinical Trials as Topic; Edema; Humans; Mouth; Pain; Papain; Placebos; Postoperative Complications; | 1976 |
A defence of the small clinical trial: evaluation of three gastroenterological studies.
Topics: Adult; Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Colonic Diseases, Functi | 1986 |
Ibuprofen in rheumatoid arthritis. Clinical study of analgesic and anti-inflammatory activity.
Topics: Adult; Aged; Alanine Transaminase; Arthritis, Rheumatoid; Aspartate Aminotransferases; Aspirin; Doub | 1968 |
Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Humans; Joints; Methods; Movement; Pain; P | 1968 |
[On the evaluation of the effect of a combination of salicylates and prednisolone in rheumatic diseases].
Topics: Acute Disease; Arthritis, Rheumatoid; Bone Diseases; Clinical Trials as Topic; Drug Synergism; Human | 1968 |
Evaluation of a simple articular index for joint tenderness in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Humans; Joints; Methods; Pain; Placebos; P | 1969 |
118 other studies available for prednisolone and Ache
Article | Year |
---|---|
Prevalence and biopsychosocial factors associated with depressive symptoms among patients living with systemic lupus erythematosus in clinical settings in urban Thailand.
Topics: Cross-Sectional Studies; Depression; Fatigue; Humans; Lupus Erythematosus, Systemic; Pain; Prednisol | 2022 |
Topics: Humans; Pain; Peripheral Nervous System Diseases; Prednisolone; Time-to-Treatment; Vasculitis | 2023 |
Trajectories of self-reported pain-related health outcomes and longitudinal effects on medication use in rheumatoid arthritis: a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD).
Topics: Analgesics, Opioid; Antirheumatic Agents; Arthritis, Rheumatoid; Australia; Cohort Studies; Female; | 2023 |
Intranasal pain in a patient with Behçet's disease.
Topics: Antiviral Agents; Behcet Syndrome; Blister; Endoscopy; Famciclovir; Female; Glucocorticoids; Herpes | 2020 |
Henoch-Schönlein purpura: Another COVID-19 complication.
Topics: Adolescent; Child; COVID-19; Humans; IgA Vasculitis; Male; Pain; Prednisolone; SARS-CoV-2 | 2021 |
Walking hyponatremia syndrome of inappropriate antidiuretic hormone secretion secondary to carbamazepine use: a case report.
Topics: Adult; Ambulatory Care; Analgesics, Non-Narcotic; Animals; Carbamazepine; Cattle; Female; Humans; Hy | 2018 |
Oesophageal pemphigoid: a rare cause of dysphagia.
Topics: Anti-Inflammatory Agents; Autoantibodies; Deglutition Disorders; Desmoglein 3; Esophageal Diseases; | 2019 |
Hunting for a cause of painful diplopia.
Topics: Aged, 80 and over; Anti-Inflammatory Agents; Diagnosis, Differential; Diplopia; Headache; Humans; Ma | 2018 |
What Is the Optimal Dose of Predniso(lo)ne for Induction of Remission in Patients With Autoimmune Hepatitis?
Topics: Acetaminophen; Hepatitis, Autoimmune; Humans; Pain; Prednisolone; Prednisone; Remission Induction | 2020 |
Osteonecrosis of the femoral head in SARS patients: seven years later.
Topics: Adult; Bone Transplantation; Disease Progression; Female; Femur Head Necrosis; Follow-Up Studies; Gl | 2013 |
Docetaxel chemotherapy for Chinese patients with castrate-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Dis | 2013 |
[Perception of pain in rheumatoid arthritis: relation to inflammation, psychic disorders, functional status, and quality of life].
Topics: Arthritis, Rheumatoid; Depression; Female; Glucocorticoids; Health Status; Humans; Inflammation; Mal | 2013 |
Pyoderma gangrenosum - a frequently misdiagnosed skin condition.
Topics: Diagnostic Errors; Glucocorticoids; Humans; Immunosuppressive Agents; Pain; Prednisolone; Pyoderma G | 2013 |
[Case report of effective intravenous immunoglobulin for lower limbs pain in steroid-resistant eosinophilic granulomatosis with polyangiitis].
Topics: Churg-Strauss Syndrome; Drug Resistance; Female; Granulomatosis with Polyangiitis; Humans; Immunoglo | 2014 |
Idiopathic carotidynia.
Topics: Anti-Inflammatory Agents; Carotid Artery, Common; Female; Humans; Inflammation; Magnetic Resonance I | 2014 |
Acute exacerbation of previously undiagnosed chronic focal myositis in an Aboriginal patient on maintenance haemodialysis.
Topics: Acute Disease; Anti-Inflammatory Agents; Biopsy; Chronic Disease; Diagnosis, Differential; Female; H | 2014 |
Bone lymphoma revealed by cruralgia during pregnancy: a case report.
Topics: Abortion, Therapeutic; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2014 |
Successful control of radicular pain in a pediatric patient with Guillain-Barré syndrome.
Topics: Administration, Oral; Child; Guillain-Barre Syndrome; Humans; Male; Pain; Prednisolone; Treatment Ou | 2015 |
Interplay between patient global assessment, pain, and fatigue and influence of other clinical disease activity measures in patients with active rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Denmark; Fatigue; Female; Humans; Male; Me | 2015 |
Chronic progressive polyarthritis in a domestic shorthair cat.
Topics: Amines; Analgesics; Animals; Anti-Inflammatory Agents; Arthritis; Buprenorphine; Cat Diseases; Cats; | 2015 |
Oral manifestations of Crohn's disease.
Topics: Azathioprine; Cheilitis; Crohn Disease; Glucocorticoids; Humans; Male; Oral Ulcer; Pain; Prednisolon | 2015 |
A patient with odynophagia and unusual endoscopic findings.
Topics: Anti-Inflammatory Agents; Deglutition Disorders; Esophageal Diseases; Esophagoscopy; Female; Glucoco | 2015 |
Summaries for Patients. Oral Prednisolone in the Treatment of Acute Gout.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Doubl | 2016 |
Case of giant cell arteritis as a manifestation of immunoglobulin G4-related disease.
Topics: Administration, Oral; Autoimmune Diseases; Female; Forehead; Giant Cell Arteritis; Glucocorticoids; | 2016 |
IgG4-related disease presenting with destructive sinonasal lesion mimicking malignancy.
Topics: Adult; Bone Diseases; Diagnosis, Differential; Endoscopy; Ethmoid Bone; Glucocorticoids; Headache Di | 2016 |
Prednisolone was equivalent to indomethacin for pain reduction in acute gout.
Topics: Acute Disease; Gout; Humans; Indomethacin; Pain; Prednisolone | 2016 |
Dentin hypersensitivity-like tooth pain seen in patients receiving steroid therapy: An exploratory study.
Topics: Adult; Dentin Sensitivity; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Pain | 2016 |
Multisystem Langerhans Cell Histiocytosis in an Adult.
Topics: Adult; Female; Histiocytosis, Langerhans-Cell; Humans; Leukocytes, Mononuclear; Pain; Prednisolone; | 2017 |
[Pharmacological treatment of Bell's palsy: favourable effects of prednisolone-based therapy now demonstrated].
Topics: Bell Palsy; Humans; Pain; Prednisolone; Quality of Life; Treatment Outcome | 2008 |
Prednisolone and naproxen both work for pain relief in acute gout.
Topics: Anti-Inflammatory Agents; Arthritis, Gouty; Clinical Trials as Topic; Double-Blind Method; Female; H | 2008 |
An unusual case of testicular pain.
Topics: Administration, Oral; Adult; Azathioprine; Diagnosis, Differential; Diuretics; Drug Therapy, Combina | 2009 |
Case of lacrimal gland inflammation associated with ulcerative colitis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Colic; Colitis, Ulcerative; Dacryocystitis; D | 2010 |
Evaluation of prednisolone treatment in the acute phase of neuralgic amyotrophy: an observational study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brachial Plexus Neuritis; Child; Cohort Studies; Female; | 2009 |
Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monocl | 2009 |
Microscopic polyangiitis initiated with liver dysfunction, calf pain and fever of unknown origin.
Topics: Administration, Oral; Antibodies, Antineutrophil Cytoplasmic; Cyclophosphamide; Dose-Response Relati | 2010 |
Skeletal morbidity in children receiving chemotherapy for acute lymphoblastic leukaemia.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Diseases; Child; Child | 2010 |
Ocular masquerade syndrome as a herald of progression of acute myelogenous leukemia.
Topics: Aged; Antineoplastic Agents; Blood Transfusion; Diagnosis, Differential; Disease Progression; Fatal | 2011 |
Lupus pernio with multiple bone cysts in the fingers.
Topics: Adult; Bone Cysts; Fingers; Granuloma; Humans; Male; Pain; Prednisolone; Radiography; Sarcoidosis; T | 2010 |
[Unilateral odynophagia in rheumatoid arthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cooperative Behavior; Deglutition Disorders; Diagnosis, | 2011 |
Painful myositis in the anti-synthetase syndrome with anti-PL12 antibodies.
Topics: Acid Phosphatase; Alanine-tRNA Ligase; Autoantibodies; Cyclophosphamide; Drug Therapy, Combination; | 2012 |
Effects of epinephrine and cortisol on the analgesic activity of metyrosine in rats.
Topics: Adrenergic beta-Antagonists; alpha-Methyltyrosine; Analgesics; Animals; Carrageenan; Chromatography, | 2011 |
Case report--progressive immobilising back and joint pain.
Topics: Adult; Ankle Joint; Anti-Inflammatory Agents; Antirheumatic Agents; Back Pain; Hip Joint; Humans; Kn | 2011 |
Osteoporosis with underlying connective tissue disease: an unusual case.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Accidental Falls; Adult; Anti-Ulcer Agents; Antibodies, Ant | 2002 |
Bilateral panuveitis in a child with hypohidrotic ectodermal dysplasia.
Topics: Child; Ectodermal Dysplasia; Epiretinal Membrane; Glucocorticoids; Humans; Hypohidrosis; Male; Pain; | 2002 |
Mumps vaccine-associated acute orchitis with accompanying idiopathic thrombocytopenic purpura.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Humans; Immunoglobulins, Intravenous; Male; M | 2002 |
[Therapy of painful conditions of the locomotor organs by prednisolone injections].
Topics: Humans; Injections; Joint Diseases; Pain; Prednisolone | 1958 |
"PAINFUL LEG" FOLLOWING STROKES.
Topics: Body Image; Cerebral Hemorrhage; Geriatrics; Humans; Hyaluronoglucosaminidase; Leg; Pain; Prednisolo | 1963 |
[DIAGNOSTIC PROBLEMS IN THE CARPAL--TUNNEL SYNDROME].
Topics: Carpal Tunnel Syndrome; Diagnosis; Female; Humans; Hydrocortisone; Injections; Median Nerve; Pain; P | 1963 |
THE REDUCTION OF POST OPERATIVE PAIN AND EDEMA IN FOOT SURGERY THROUGH LOCAL INSTILLATION OF CORTICOSTEROIDS.
Topics: Dexamethasone; Edema; Foot; Glucocorticoids; Humans; Pain; Pain, Postoperative; Postoperative Compli | 1964 |
AVASCULAR NECROSIS OF BONE COMPLICATING STEROID THERAPY.
Topics: Cortisone; Drug Therapy; Femur Head; Joint Diseases; Necrosis; Osteonecrosis; Pain; Prednisolone; Ra | 1965 |
Muscle involvement in a patient with Henoch-Schönlein purpura nephritis.
Topics: Administration, Oral; Adolescent; Anti-Inflammatory Agents; Glomerulonephritis, Membranoproliferativ | 2004 |
Intralesional treatment in painful rib metastases.
Topics: Adult; Aged; Aged, 80 and over; Anesthetics, Local; Anti-Inflammatory Agents; Bone Neoplasms; Humans | 2004 |
[Therapy of painful bone metastases in patients with prostate carcinoma. The AP 32/02 Study of the AUO].
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Male; Mitoxantrone; | 2004 |
Clinical quiz: a pediatric case presenting with fever and diffuse myalgia.
Topics: Anti-Inflammatory Agents; Child; Familial Mediterranean Fever; Female; Humans; Muscular Diseases; Pa | 2005 |
[Tolosa-Hunt syndrome: analysis of six cases].
Topics: Adult; Diagnosis, Differential; Female; Follow-Up Studies; Glucocorticoids; Humans; Magnetic Resonan | 2005 |
Prostanoids as friends, not foes: further evidence from the interference by cycloxygenase-inhibitory drugs when inducing tolerance to experimental arthritigens in rats.
Topics: Administration, Oral; Animals; Arthritis, Experimental; Aspirin; Celecoxib; Cyclooxygenase 2; Cycloo | 2005 |
[A case of fibromyalgia treated with medical and autogenic training].
Topics: Adult; Anti-Dyskinesia Agents; Anti-Inflammatory Agents; Autogenic Training; Botulinum Toxins; Combi | 2005 |
Bortezomib-induced Sweet's syndrome.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration | 2005 |
Still looking for the cause of fever?
Topics: Dyspnea; Fever; Glucocorticoids; Humans; Leukocytosis; Male; Middle Aged; Muscle, Skeletal; Pain; Pr | 2006 |
Knee pain and swelling secondary to ulcerative colitis.
Topics: Adult; Arthritis; Colitis, Ulcerative; Colonoscopy; Diagnosis, Differential; Fever; Glucocorticoids; | 2007 |
An unusual complication of intra-articular injections of corticosteroids: Tachon syndrome. Two case reports.
Topics: Arthralgia; Elbow Joint; Glucocorticoids; Humans; Injections, Intra-Arterial; Low Back Pain; Male; M | 2007 |
Herpes zoster in the elderly.
Topics: Adolescent; Adult; Aged; Child; Depression; Facial Paralysis; Herpes Zoster; Humans; Middle Aged; Pa | 1967 |
Malignant mesothelioma of the pleura: clinical aspects and symptomatic treatment.
Topics: Adult; Aged; Bleomycin; Female; Fever; Humans; Male; Mesothelioma; Middle Aged; Pain; Pleura; Pleura | 1984 |
[Pain on the right side of the neck].
Topics: Adult; Diagnosis, Differential; Female; Humans; Male; Neck; Pain; Prednisolone; Thyroiditis | 1983 |
Juxtapapillary chorioretinitis in neurosyphilis. A case report.
Topics: Adult; Chorioretinitis; Eye; Fluorescein Angiography; Humans; Male; Neurosyphilis; Pain; Penicillin | 1984 |
Pyrexia, abdominal pain and splenomegaly.
Topics: Abdomen; Adult; Anemia, Hemolytic, Autoimmune; Female; Fever; Humans; Pain; Prednisolone; Splenomega | 1983 |
Diagnoses not to be missed: giant cell arteritis.
Topics: Aged; Biopsy; Blood Sedimentation; Giant Cell Arteritis; Headache; Humans; Pain; Polymyalgia Rheumat | 1982 |
[A case of Sweet syndrome with severe muscular pain].
Topics: Aged; Humans; Male; Muscles; Pain; Prednisolone; Sweet Syndrome | 1995 |
Effective treatment of painful bone crises in type I gaucher's disease with high dose prednisolone.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Bone Diseases; Child; Drug Therapy, Combination; Gauche | 1996 |
Painful and painless ophthalmoplegia with cavernous sinus pseudotumour.
Topics: Adolescent; Anti-Inflammatory Agents; Child; Humans; Magnetic Resonance Imaging; Male; Ophthalmopleg | 1996 |
Glaucomatocyclitic crisis in a child.
Topics: Adolescent; Clonidine; Corneal Edema; Diagnosis, Differential; Drug Therapy, Combination; Glaucoma; | 1998 |
Commentary: low-dose high-frequency enzyme replacement therapy prevents fractures without complete suppression of painful bone crises in patients with severe juvenile onset type I Gaucher disease.
Topics: Adolescent; Adult; Age Factors; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Ste | 1998 |
Calcitonin and mandibular bone resorption in systemic sclerosis.
Topics: Bone Resorption; Calcitonin; Captopril; Female; Humans; Jaw; Mandible; Middle Aged; Pain; Prednisolo | 1999 |
[Painful ischemia of the extremities with T-cell lymphoma].
Topics: Chlorambucil; Female; Foot; Hand; Humans; Ischemia; Lymphoma, T-Cell; Male; Middle Aged; Pain; Predn | 1999 |
Oral corticosteroids and bone pain after pamidronate in adults with cystic fibrosis.
Topics: Adult; Anti-Infective Agents; Bone Diseases; Cystic Fibrosis; Diphosphonates; Glucocorticoids; Human | 1999 |
Recurrent steroid-responsive trismus and painful ophthalmoplegia.
Topics: Anti-Inflammatory Agents; Female; Humans; Inflammation; Magnetic Resonance Imaging; Middle Aged; Oph | 1999 |
Recurrent Tolosa-Hunt syndrome: a report of ten new cases.
Topics: Anti-Inflammatory Agents; Brain; Cranial Nerves; Demography; Female; Humans; Inflammation; Magnetic | 1999 |
Congenital synostosis between the scaphoid and the trapezium as a cause of tenosynovitis simulating de Quervain's disease.
Topics: Adult; Anti-Inflammatory Agents; Carpal Bones; Diagnosis, Differential; Female; Humans; Pain; Predni | 2000 |
Editorial: Injecting the painful shoulder.
Topics: Adrenal Cortex Hormones; Humans; Hydrocortisone; Injections, Intra-Articular; Pain; Prednisolone; Sh | 1976 |
Medijector--a new method of corticosteroid-anesthetic delivery.
Topics: Anesthetics, Local; Dexamethasone; Drug Therapy, Combination; Glucocorticoids; Humans; Injections, J | 1979 |
Remittent painful ophthalmoplegia: the Tolosa-Hunt syndrome? A report of seven cases and review of the literature.
Topics: Actinomycosis; Adolescent; Adult; Cavernous Sinus; Cerebral Angiography; Female; Granuloma; Humans; | 1979 |
The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation.
Topics: Chlorambucil; Drug Therapy, Combination; Estramustine; Humans; Male; Nausea; Neoplasm Metastasis; Ni | 1979 |
Painful shoulders and painful arcs.
Topics: Humans; Joint Diseases; Pain; Prednisolone; Shoulder; Terminology as Topic | 1977 |
Myelomatosis.
Topics: Acute Kidney Injury; Alkylating Agents; Amyloidosis; Antigens, Neoplasm; Blood Viscosity; Bone and B | 1977 |
Evaluation of analgesic agents in rats with adjuvant arthritis.
Topics: Amphetamine; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Na | 1975 |
[Two cases of painful ophthalmoplegic syndrome].
Topics: Adult; Female; Humans; Meningitis; Middle Aged; Ophthalmoplegia; Pain; Prednisolone; Sinusitis | 1975 |
Tolosa-Hunt syndrome. The dangers of an eponym.
Topics: Aneurysm; Carotid Artery Diseases; Diagnosis, Differential; Female; Humans; Lymphoma; Male; Middle A | 1975 |
Myalgia as the major symptom in systemic panniculitis (Weber-Christian disease).
Topics: Adipose Tissue; Biopsy; Humans; Male; Middle Aged; Muscles; Muscular Diseases; Neurologic Examinatio | 1992 |
[L-tryptophan-induced eosinophilia-myalgia syndrome with features of diffuse fasciitis with eosinophilia].
Topics: Eosinophilia; Fasciitis; Female; Humans; Middle Aged; Pain; Prednisolone; Tryptophan | 1990 |
Distribution of pain provoked from lumbar facet joints and related structures during diagnostic spinal infiltration.
Topics: Back Pain; Humans; Injections, Spinal; Lidocaine; Lumbar Vertebrae; Nerve Block; Pain; Pain Measurem | 1989 |
An unusual case of painful ophthalmoplegia in a patient with rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Diplopia; Eye Movements; Female; Humans; Lupus Erythematosus, Systemic | 1989 |
Ultrastructural features of the osteoid of patients with fibrogenesis imperfecta ossium.
Topics: Biopsy; Bone and Bones; Bone Diseases; Calcification, Physiologic; Calcitriol; Collagen; Humans; Mal | 1989 |
Compartment syndrome as a late complication of eosinophilic fasciitis.
Topics: Adult; Compartment Syndromes; Eosinophilia; Fasciitis; Humans; Leg; Male; Pain; Prednisolone; Pressu | 1989 |
The painful thyroid.
Topics: Aspirin; Humans; Pain; Prednisolone; Thyroiditis | 1986 |
[Strategy for using glucocorticoid preparations in neuromuscular diseases].
Topics: Autoimmune Diseases; Humans; Multiple Sclerosis; Muscular Diseases; Myositis; Nerve Compression Synd | 1985 |
Hyperalgesic properties of 15-lipoxygenase products of arachidonic acid.
Topics: Animals; Arachidonate Lipoxygenases; Arachidonic Acid; Arachidonic Acids; Cyclooxygenase Inhibitors; | 1986 |
Five patients with painless thyroiditis simultaneously developed in a nursery school.
Topics: Adult; Antibodies, Viral; Female; Humans; Male; Middle Aged; Pain; Prednisolone; Schools, Nursery; T | 1988 |
[Syndrome of perforating lateral branches of the subcostal and ilio-hypogastric nerves. An unrecognized cause of hip pain].
Topics: Arthritis; Diagnosis, Differential; Female; Hip; Hip Joint; Humans; Lidocaine; Lumbosacral Plexus; M | 1986 |
[Clinical picture and treatment of lesions of the epidural space in lymphosarcoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Daunorubi | 1986 |
[A case of idiopathic retroperitoneal fibrosis associated with localized swelling and pain on bilateral lower legs].
Topics: Female; Humans; Leg; Middle Aged; Pain; Prednisolone; Retroperitoneal Fibrosis; Ureter | 1985 |
Effort angina without coronary obstruction in a patient with Takayasu's aortitis: a case report.
Topics: Adult; Angina Pectoris; Angiography; Aortitis; Coronary Disease; Electrocardiography; Female; Hemody | 1985 |
Delayed onset of polymyalgia in polymyalgia rheumatica.
Topics: Aged; Blood Sedimentation; Female; Globulins; Hemoglobins; Humans; Middle Aged; Pain; Polymyalgia Rh | 1986 |
A case of ulcerative colitis presenting as vasculitic purpura.
Topics: Barium Sulfate; Colectomy; Colitis, Ulcerative; Diarrhea; Humans; Intestinal Mucosa; Male; Middle Ag | 1985 |
The drug therapy of ulcerative colitis and of Crohn's disease.
Topics: Adrenocorticotropic Hormone; Atropine; Azathioprine; Colitis, Ulcerative; Crohn Disease; Diarrhea; D | 1974 |
Cutaneous manifestations in capillary dilatation and endovascular fibrin deposits.
Topics: Angiomatosis; Anticoagulants; Arm; Biopsy; Blindness; Blood Coagulation Disorders; Capillaries; Chro | 1968 |
[Combined drug therapy in highly acute attacks of pain in the course of rheumatic diseases].
Topics: Acute Disease; Aminopyrine; Arthritis, Rheumatoid; Dexamethasone; Drug Combinations; Female; Humans; | 1974 |
[Irritations of the iliosacral joint, their symptomatics and therapy].
Topics: Acute Disease; Administration, Topical; Adolescent; Adult; Anti-Inflammatory Agents; Arthritis, Rheu | 1970 |
Case of glomerulonephritis associated with acute toxoplasmosis.
Topics: Acute Disease; Animals; Antigens; Biopsy; Child; Edema; Fever; Fluorescent Antibody Technique; Glome | 1974 |
Treatment of sting ray wounds.
Topics: Anaphylaxis; Animals; Bites and Stings; Fishes, Poisonous; Histamine H1 Antagonists; Humans; Pain; P | 1970 |
Blood and neoplastic diseases. Myelomatosis.
Topics: Blood Viscosity; Bone Diseases; Cyclophosphamide; Fluorides; Humans; Hypercalcemia; Melphalan; Multi | 1974 |
[Corticoids and local anesthetics in antalgic therapy. Changes in relationship between solutions].
Topics: Adrenal Cortex Hormones; Anesthetics, Local; Drug Interactions; Humans; Hydrocortisone; Hydrogen-Ion | 1973 |
Toad poisoning in small animals.
Topics: Animals; Anura; Atropine; Cat Diseases; Cats; Chloramphenicol; Dog Diseases; Dogs; Ethiopia; Female; | 1973 |
Arthralgia and myalgia in mumps.
Topics: Acetaminophen; Adult; Arthritis; Blood Cell Count; Fever; Hematocrit; Hemoglobins; Humans; Male; Mum | 1973 |
Painful ophthalmoplegia.
Topics: Acute Disease; Adolescent; Adult; Aged; Child; Chronic Disease; Cranial Nerves; Female; Functional L | 1970 |
[Experiences with a combination of oxyphenbutazone and prednisolone in painful diseases of the locomotor system].
Topics: Humans; Joint Diseases; Oxyphenbutazone; Pain; Prednisolone | 1970 |
[Indications for local corticosteroid therapy in tendopathies in athletes].
Topics: Acetates; Achilles Tendon; Adult; Athletic Injuries; Dexamethasone; Humans; Ligaments, Articular; Ma | 1970 |
[C.P.C. No. 150. Chief complaints: anemia, shortness of breath and right upper abdominal pain].
Topics: Abdomen; Aged; Anemia, Aplastic; Humans; Male; Pain; Peptic Ulcer; Prednisolone; Respiration | 1969 |
Vincristine-induced neuropathy. A clinical study of fifty leukemic patients.
Topics: Achilles Tendon; Action Potentials; Adult; Child; Child, Preschool; Cranial Nerves; Drug Synergism; | 1969 |